Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate.
Pure red cell aplasia (PRCA) is characterized by anemia with reticulocytopenia but with normal leukocyte and platelet counts, and a bone marrow with a selective absence of erythroid precursor cells. Drug-induced PRCA is a rare secondary form of PRCA, and is usually acute and fully reversible by the withdrawal of the causative drugs. We report a rare case of PRCA in a prostate cancer patient treated with combined androgen blockade (CAB) consisted of leuprolide acetate as a luteinizing hormone-releasing hormone agonist and chlormadinone acetate as an antiandrogen. This case demonstrated that these drugs could be a cause of PRCA, and suggests that regular close monitoring for anemia is needed in prostate cancer patients treated with these drugs.
Kobayashi
Minoru
M
Department of Urology, Sano Kosei General Hospital, Japan. minoruk@jichi.ac.jp
Nukui
Akinori
A
Morita
Tatsuo
T
D000230:Adenocarcinoma / Q000628:therapy; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D017707:Erythrocyte Transfusion; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000628:therapy
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D002715:Chlormadinone Acetate; D016729:Leuprolide